TP53 and Li-Fraumeni Syndrome: Inherited-Risk Context

TP53 Biology Versus Inherited Predisposition

TP53 encodes p53, a stress-responsive transcription factor that can pause the cell cycle, coordinate DNA repair, trigger senescence, or activate apoptosis. Somatic TP53 alterations are common across many tumour types and usually arise only in the cancer. A somatic finding therefore describes tumour biology, not automatically the person's inherited risk.

LFS is different: a pathogenic TP53 variant is present in the germline and can be found in normal tissue as well as tumour. Inheritance is typically autosomal dominant, although de novo variants and mosaic results require careful specialist interpretation. Variant classification—not the gene name alone—determines whether a result is clinically meaningful.

When Germline Testing Enters the Conversation

A genetics professional may consider germline testing when personal or family history suggests LFS, when a tumour result is unusual for the clinical setting, or when testing criteria in the relevant guideline are met. Tumour sequencing can raise the question, but it is not a substitute for a validated germline sample and pre- and post-test counselling.

A blood result can occasionally be complicated by clonal haematopoiesis, mosaicism, or a variant of uncertain significance (VUS). A VUS is not the same as a pathogenic result and should not be used alone to change surgery, screening, or relatives' care. The laboratory and genetics team should interpret the result with the family history and assay context.

Surveillance and Family Communication

The NCI PDQ linked below describes structured surveillance for people with LFS, including regular clinical review and age-appropriate imaging. The exact schedule depends on age, prior cancers, family history, previous treatments, and local specialist practice. The purpose of a surveillance protocol is earlier detection; it is not a guarantee that cancer will be prevented.

Because a confirmed germline result can affect relatives, cascade testing is usually offered through a genetics service. Family communication should use the exact laboratory classification and a written plan rather than a simplified message such as 'everyone has the gene'. Privacy, consent, and psychosocial support are part of responsible testing.

What This Page Cannot Establish

This page cannot determine whether an individual TP53 variant is pathogenic, whether a tumour-only result is inherited, or which surveillance schedule is appropriate. Those questions require the original report, a three-generation history where possible, and a qualified genetics or oncology team.

Key Takeaways

• ·Most tumour TP53 alterations are somatic; Li-Fraumeni syndrome requires an inherited-risk interpretation of a germline result.
• ·Variant classification, specimen, assay, and family history all matter; a VUS is not a pathogenic diagnosis.
• ·NCI describes structured surveillance for LFS, but an individual's schedule must be specialist-led.
• ·A confirmed germline result can inform relatives through genetics-led cascade testing and counselling.